{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:31:26Z","timestamp":1787725886879,"version":"build-2784847793"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging"],"abstract":"<jats:p>\n                    Telomerase is a key regulator of both cellular immortality and aging, making it an attractive target for cancer therapy and age associated pathologies. Its clinical exploitation has been limited by structural complexity and challenges in achieving specificity. Recent structural insights into human telomerase reverse transcriptase (hTERT) have enabled the identification of selective inhibitors. Here, we repurposed MK0873, a PDE4 inhibitor previously evaluated in Phase II clinical trials for rheumatoid arthritis and COPD, as a non covalent telomerase targeting agent.\n                    <jats:italic>In silico<\/jats:italic>\n                    docking and molecular dynamics simulations predicted stable binding of MK0873 to hTERT, distinct from the covalent interaction of BIBR1532. Analysis of neuroblastoma datasets revealed that high TERT expression correlates with poorer survival, independent of MYCN amplification. MK0873 reduced proliferation of hTERT positive cells, promoted cellular senescence and decreased relative telomere length, whereas ALT positive cells exhibited minimal response, supporting selective activity in telomerase dependent cellular models. Importantly, direct biochemical assessment using the Telomeric Repeat Amplification Protocol assay demonstrated a significant reduction in telomerase activity following MK0873 treatment, providing experimental evidence that complements the computational predictions and cellular phenotypes observed in this study. Although the magnitude of telomerase inhibition was lower than that of the reference inhibitor BIBR1532 under identical experimental conditions, the combined computational, biochemical and cellular findings consistently support hTERT as a relevant molecular target of MK0873. Collectively, these results provide proof of concept evidence that MK0873 represents a promising lead scaffold for non covalent targeting of hTERT. While additional studies are required to further define cellular target engagement, distinguish potential PDE4 dependent effects and optimize inhibitory potency. Current work establishes a foundation for the continued development of MK0873 derived compounds as potential telomerase targeted anticancer therapeutics.\n                  <\/jats:p>","DOI":"10.3389\/fragi.2026.1783019","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:03:59Z","timestamp":1787724239000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Repurposing MK0873 as a non-covalent hTERT-Targeting compound: a proof of concept study"],"prefix":"10.3389","volume":"7","author":[{"given":"Maham","family":"Ansari","sequence":"first","affiliation":[{"name":"Department of Biotechnology, Faculty of Life Sciences and Informatics, Balochistan University of Information Technology, Engineering and Management Sciences (BUITEMS)","place":["Quetta, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Wali","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Faculty of Life Sciences and Informatics, Balochistan University of Information Technology, Engineering and Management Sciences (BUITEMS)","place":["Quetta, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohhamed","family":"Rasul","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health Karolinska Institutet","place":["Stockholm, Sweden"]},{"name":"Department of Pharmaceutical Basic Science, Faculty of Pharmacy, Tishk International University","place":["Erbil, Iraq"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Gemzell Danielsson","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health Karolinska Institutet","place":["Stockholm, Sweden"]},{"name":"Department of Gynecology and Reproductive Medicine, Karolinska University Hospital","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Twana","family":"Alkasalias","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health Karolinska Institutet","place":["Stockholm, Sweden"]},{"name":"General Directorate of Scientific Research Center, Salahaddin University-Erbil","place":["Erbil, Iraq"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Mushtaq","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Faculty of Life Sciences and Informatics, Balochistan University of Information Technology, Engineering and Management Sciences (BUITEMS)","place":["Quetta, Pakistan"]},{"name":"Department of Microbiology Tumor and Cell Biology, Karolinska Institutet","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1007\/s00018-016-2146-9","article-title":"Reactivation of telomerase in cancer","volume":"73","author":"Akincilar","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3390\/genes11030304","article-title":"G-quadruplex stabilization fuels the ALT pathway in ALT-Positive osteosarcoma cells","volume":"11","author":"Amato","year":"2020","journal-title":"Genes"},{"key":"B4","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"B5","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0959-8049(97)00065-8","article-title":"Telomere dynamics and telomerase activity in in vitro immortalised human cells","volume":"33","author":"Bryan","year":"1997","journal-title":"Eur. Journal Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1016\/j.str.2015.08.006","article-title":"Structural basis of telomerase inhibition by the highly specific BIBR1532","volume":"23","author":"Bryan","year":"2015","journal-title":"Structure"},{"key":"B7","doi-asserted-by":"publisher","first-page":"5423","DOI":"10.1021\/jm025563v","article-title":"Telomerase inhibition, telomere shortening, and decreased cell proliferation by cell permeable 2\u2018-O-Methoxyethyl oligonucleotides","volume":"45","author":"Chen","year":"2002","journal-title":"J. Med. Chem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/med.21626","article-title":"Therapeutic strategies for targeting telomerase in cancer","volume":"40","author":"Chen","year":"2020","journal-title":"Med. Res. Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/s0092-8674(00)80762-x","article-title":"p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis","volume":"97","author":"Chin","year":"1999","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cells8010019","article-title":"Oxidative stress induces telomere dysfunction and senescence by replication fork arrest","volume":"8","author":"Coluzzi","year":"2019","journal-title":"Cells"},{"key":"B11","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1021\/tx0000872","article-title":"Telomerase: an unusual target for cytotoxic agents","volume":"13","author":"Corey","year":"2000","journal-title":"Chem. Res. Toxicol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/pharmaceutics16010023","article-title":"Phosphodiesterase-4 inhibition in the management of psoriasis","volume":"16","author":"Crowley","year":"2023","journal-title":"Pharmaceutics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1093\/emboj\/20.24.6958","article-title":"A highly selective telomerase inhibitor limiting human cancer cell proliferation","volume":"20","author":"Damm","year":"2001","journal-title":"Embo J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"8262","DOI":"10.1038\/sj.onc.1206054","article-title":"Telomere dysfunction and telomerase reactivation in human leukemia cell lines after telomerase inhibition by the expression of a dominant-negative hTERT mutant","volume":"21","author":"Delhommeau","year":"2002","journal-title":"Oncogene"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/jcb.27089","article-title":"Investigation of the effect of telomerase inhibitor BIBR1532 on breast cancer and breast cancer stem cells","volume":"120","author":"Do\u011fan","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"B16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/978-1-60327-070-0_6","article-title":"Telomerase inhibition and telomere targeting in hematopoietic cancer cell lines with small non-nucleosidic synthetic compounds (BIBR1532)","volume":"405","author":"El Daly","year":"2007","journal-title":"Methods Mol. Biol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1182\/blood-2003-12-4322","article-title":"Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532","volume":"105","author":"El-Daly","year":"2005","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"109157","DOI":"10.1016\/j.bioorg.2025.109157","article-title":"Design, synthesis, and antitumor evaluation of new pyridazinone scaffolds as dual EGFR\/VEGFR-2 kinase inhibitors and apoptotic cells inducers","volume":"166","author":"Ewieda","year":"2025","journal-title":"Bioorg Chem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"109486","DOI":"10.1016\/j.bioorg.2026.109486","article-title":"Discovery of novel pyridazinone derivatives as EGFRWT\/EGFRT790M kinase inhibitors; design, synthesis, antitumor evaluation, and molecular dynamic simulations","volume":"170","author":"Ewieda","year":"2026","journal-title":"Bioorg. Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrc2275","article-title":"Telomerase and cancer therapeutics","volume":"8","author":"Harley","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1472906","article-title":"Telomere maintenance and the DNA damage response: a paradoxical alliance","volume":"12","author":"Harman","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s13277-013-0757-4","article-title":"Telomerase as a useful target in cancer fighting\u2014the breast cancer case","volume":"34","author":"Holysz","year":"2013","journal-title":"Tumor Biology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13073-016-0324-x","article-title":"Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies","volume":"8","author":"Jafri","year":"2016","journal-title":"Genome Med."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/mps3020027","article-title":"An optimised step-by-step protocol for measuring relative telomere length","volume":"3","author":"Joglekar","year":"2020","journal-title":"Methods Protoc."},{"key":"B26","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1006\/jmbi.1996.0897","article-title":"Development and validation of a genetic algorithm for flexible docking","volume":"267","author":"Jones","year":"1997","journal-title":"J. Mol. Biol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/nar\/gks1121","article-title":"Eroded human telomeres are more prone to remain uncapped and to trigger a G2 checkpoint response","volume":"41","author":"Jullien","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.ejca.2004.11.024","article-title":"Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects","volume":"41","author":"Kelland","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1126\/science.7605428","article-title":"Specific association of human telomerase activity with immortal cells and cancer","volume":"266","author":"Kim","year":"1994","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","article-title":"DrugBank 6.0: the DrugBank knowledgebase for 2024","volume":"52","author":"Knox","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e586","DOI":"10.1038\/cddis.2013.84","article-title":"Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma","volume":"4","author":"Kocak","year":"2013","journal-title":"Cell Death Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.7150\/jca.13054","article-title":"Knockdown of hTERT and treatment with BIBR1532 inhibit cell proliferation and invasion in endometrial cancer cells","volume":"6","author":"Kong","year":"2015","journal-title":"J. Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3892\/br.2015.463","article-title":"Absence of telomerase reverse transcriptase promoter mutations in neuroblastoma","volume":"3","author":"Lindner","year":"2015","journal-title":"Biomed. Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1126\/science.276.5312.561","article-title":"Reverse transcriptase motifs in the catalytic subunit of telomerase","volume":"276","author":"Lingner","year":"1997","journal-title":"Science"},{"key":"B35","doi-asserted-by":"publisher","first-page":"E6231","DOI":"10.1073\/pnas.1701848114","article-title":"Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery","volume":"114","author":"Mateus","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"134216","DOI":"10.1016\/j.molstruc.2022.134216","article-title":"Design, synthesis and chemoinformatic studies of new thiazolopyrimidine derivatives as potent anticancer agents via phosphodiesterase-5 inhibition and apoptotic inducing activity","volume":"1272","author":"Nemr","year":"2023","journal-title":"J. Mol. Struct."},{"key":"B37","doi-asserted-by":"publisher","first-page":"4765","DOI":"10.1007\/s11030-024-11016-2","article-title":"An overview on pharmaceutical applications of phosphodiesterase enzyme 5 (PDE5) inhibitors","volume":"29","author":"Nemr","year":"2025","journal-title":"Mol. Divers"},{"key":"B38","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1039\/c8md90019a","article-title":"What are the drugs of the future?","volume":"9","author":"Ngo","year":"2018","journal-title":"Medchemcomm"},{"key":"B39","doi-asserted-by":"publisher","first-page":"15566","DOI":"10.1074\/jbc.M201266200","article-title":"Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate","volume":"277","author":"Pascolo","year":"2002","journal-title":"J. Biol. Chem."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1164\/ajrccm.163.5.2101039","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI\/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary","volume":"163","author":"Pauwels","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/sj.bjp.0707374","article-title":"Telomerase and its potential for therapeutic intervention","volume":"152","author":"Phatak","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B43","doi-asserted-by":"publisher","first-page":"11779322241267056","DOI":"10.1177\/11779322241267056","article-title":"Nilotinib: disrupting the MYC-MAX heterocomplex","volume":"18","author":"Shah","year":"2024","journal-title":"Bioinform Biol. Insights"},{"key":"B44","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/S0959-8049(97)00062-2","article-title":"A survey of telomerase activity in human cancer","volume":"33","author":"Shay","year":"1997","journal-title":"Eur. Journal Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/sj.bjc.6604209","article-title":"Targeting telomerase for cancer therapeutics","volume":"98","author":"Shay","year":"2008","journal-title":"Br. J. Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/s1535-6108(02)00159-9","article-title":"Telomerase: a target for cancer therapeutics","volume":"2","author":"Shay","year":"2002","journal-title":"Cancer Cell"},{"key":"B47","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s11523-015-0364-y","article-title":"A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines","volume":"10","author":"Shi","year":"2015","journal-title":"Target. Oncol."}],"container-title":["Frontiers in Aging"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fragi.2026.1783019\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:04:00Z","timestamp":1787724240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fragi.2026.1783019\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":47,"alternative-id":["10.3389\/fragi.2026.1783019"],"URL":"https:\/\/doi.org\/10.3389\/fragi.2026.1783019","relation":{},"ISSN":["2673-6217"],"issn-type":[{"value":"2673-6217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"1783019"}}